Amyloid-β (Aβ) precursor protein (APP ... dietary or pharmacological methods can limit Alzheimer's disease (AD)-like pathology. Synaptic zinc is involved in the metabolism of Aβ and in the ...

The a-secretase cleavage site lies within the amyloid-beta peptide associated with Alzheimer plaques. Therefore, an increase in asecretase activity has been found to be associated with a decrease ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

Researchers have developed engineered human microglia that detect disease-related brain changes and release therapeutic ...

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented the rational design of an Alzheimer’s ...

The following is a summary of “Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease,” ...

A new way to deliver disease-fighting proteins throughout the brain may improve the treatment of Alzheimer's disease and other neurological disorders, according to University of California, Irvine ...

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns ...

The drug, called trontinemab, showed in the study that it could achieve rapid and deep reductions in amyloid beta plaques in the brain, one of the characteristics of Alzheimer's. Roche said its ...

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These are good proteins gone bad," Klein said. "They are good proteins ...

Promis Neurosciences Inc. recently presented the rational design of an Alzheimer’s disease (AD) vaccine candidate maximizing the selective targeting of toxic amyloid-β oligomers.